Loading

Co-opting Biological Processes to Drug Cancer and Other Diseases

June 05, 2024
Breakout Session
Oncology
26B
Co-opting of biological processes opened some of the most fruitful areas of drug discovery, from the wildly successful degraders that utilize the E3 ligase-proteasome pathway to Argenx's Vyvgart that uses FcRn-mediated IgG recycling to treat autoimmune diseases. In this session, panelists will discuss a new generation of approaches that cleverly exploit biological processes -- from novel intra- and extracellular degraders to sequence-specific inhibitors of protein synthesis to pH-engineered ADCs that recycle their targets back to cell surface for more payload pickup.
Speakers
Mariana Mihalusova, PhD
Investor
Venrock
Speakers
Bernd Boidol, PhD
CEO
Proxygen
George Eliades, PhD
CEO
Mythic Therapeutics, Inc.
Larry Hamann, PhD
Co-founder/CEO
Interdict Bio
Aetna Wun Trombley, Ph.D.
CEO
Lycia
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS